Anton A. Shmalts

Dr. Anton A. Shmalts

methodology
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
TMTamila V. Martynyuk
Tamila V. Martynyuk
ZVZ. S. Valieva
Z. S. Valieva
VAV. A. Azizov
V. A. Azizov
RAR. S. Akchurin
R. S. Akchurin
ОВО. Я. Васильцева
О. Я. Васильцева
DisclaimerThe EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

11 March 2024 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
TMTamila V. Martynyuk
Tamila V. Martynyuk
Anton A. ShmaltsAnton A. Shmalts
Anton A. Shmalts
VGV. V. Gramovich
V. V. Gramovich
NDN. M. Danilov
N. M. Danilov
ICI. E. Chernogrivov
I. E. Chernogrivov
Евразийские рекомендации по диагностике и лечению лёгочной гипертензии (2023)

29 June 2017 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
SGSergey V. Gorbachevsky
Sergey V. Gorbachevsky
Anton A. ShmaltsAnton A. Shmalts
Anton A. Shmalts
IBIrina Y. Barishnikova
Irina Y. Barishnikova
Sergey ZaetsSergey Zaets
Sergey Zaets
Since 2004, different techniques for the Potts shunt have been used in patients with incurable pulmonary arterial hypertension. However, the experience with these interventions in a single institution is limited. We present our series of Potts shunts in children with pulmonary arterial hypertension. Eight patients with suprasystemic pulmonary arterial hypertension (pulmonary artery-to-aorta mean pressure ratio of 1.39 ± 0.30) had a Potts shunt at the median age of 13.5 months. Six patients were followed up for 2–32 (median 17) months after the operation. In all cases, the Potts shunt caused a decrease in arterial blood oxygen saturation at the lower extremities and was the genesis of the arterial blood oxygen saturation gradient between the upper and lower extremities (10.5 ± 1.8% at discharge). Postoperative echocardiography revealed flattening of the ventricular septum as well as a decrease in the right ventricle-to-left ventricle end-diastolic diameter ratio from 1.36 ± 0.14 preoperatively to 0.99 ± 0.22 at discharge (P = 0.010). The 2 patients with the highest preoperative pulmonary artery-to-aorta mean pressure ratio (1.79–1.86) died during the early postoperative period from repeated pulmonary hypertension crises and uncontrolled hypoxaemia. There were no deaths during the follow-up period. The paediatric functional class of the patients improved from IIIb–IV to I–II, syncopal episodes no longer persisted and the weight deficit decreased from 21.8 ± 7.5% preoperatively to 11.5 ± 5.9% at the latest follow-up examination (P = 0.004). The arterial blood oxygen saturation gradient between the upper and lower extremities and the right ventricle-to-left ventricle end-diastolic diameter ratio were the same as they were while the patients were in the hospital. Our limited experience demonstrates that the Potts shunt lowers suprasystemic pulmonary hypertension to the systemic level, limits manifestations of right-sided heart failure and improves the overall functional status of the patients.

21 September 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
SGSergey V. Gorbachevsky
Sergey V. Gorbachevsky
Anton A. ShmaltsAnton A. Shmalts
Anton A. Shmalts
GDGulamjan M. Dadabaev
Gulamjan M. Dadabaev
Nasirullo NishonovNasirullo Nishonov
Nasirullo Nishonov
MPManolis G. Pursanov
Manolis G. Pursanov
Sergey ZaetsSergey Zaets
Sergey Zaets
The aim of this study was to analyze results of stenting atrioseptostomy in patients with pulmonary arterial hypertension and a different level of risk for one-year mortality that is not well described. Patients that underwent atrioseptostomy with stenting were retrospectively divided in two groups: “intermediate” (n = 55) or “high” risk (n = 13), according to the 2015 ESC/ESR guideline. Results of atrioseptostomy were assessed during hospital period and at follow-up. Patients from “intermediate” risk group demonstrated lower mortality rate (10/55, vs. 6/13) during the course of the study period, as well as higher freedom from lung transplantation or Potts shunt. At discharge, patients of both groups presented improvement in functional class and mobility. Patients from “intermediate” risk group showed longer 6-min walking distance, and lower levels of brain natriuretic peptide. At the latest follow-up, stable position and full patency of stents with right-to-left or bidirectional shunt at atrial level and absence of syncope was confirmed in patients of both groups. Patients from the “intermediate” risk group demonstrated higher functional class, better performance of walking test, and lower levels of brain natriuretic peptide. Stenting atrioseptostomy reliably secured interatrial communication and improved clinical condition in patients with idiopathic pulmonary arterial hypertension. Mid-term results were better in “intermediate” risk group.

15 December 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
Anton A. ShmaltsAnton A. Shmalts
Anton A. Shmalts
SGS. V. Gorbachevsky
S. V. Gorbachevsky
ШАШмальц Антон Алексеевич
Шмальц Антон Алексеевич
Pulmonary arterial hypertension (PAH) is severe and often times rapidly progressive disease with fatal outcome. The concept of initial combination of PAH-specific therapies in high risk patients at baseline was first described in the European guidelines on pulmonary hypertension (PH) in 2009, and in low or intermediate risk patients at baseline in 2015. Interestingly, that in Cologne Experts Consensus, and then in the 6th World Symposium on PH medical community started considering initial combination therapy as one of the most important pillars in PAH treatment algorithms in 2018. As of August 2020, as many as 8 formulations of 7 reference PAH-specific drugs are licensed for medical use in the Russian Federation. On top of that, 6 abbreviated drugs (generics) have also become available few years ago. Unfortunately, intravenous and subcutaneous prostacyclin analogs (PCA) and tadalafil are not approved for PH patients treatment in the Russian Federation. In this narrative review paper we attempted to describe studies on initial dual combination therapy with PAH-specific drugs registered in Russia, i.e. ambrisentan and riociguat, macitentan and riociguat, macitentan and sildenafil in low or intermediate risk patients at baseline, as well as iloprost inhaled and sildenafil, iloprost inhaled and bosentan in high risk patients. Some beneficial pharmacological effects due to the synergy between ambrisentan plus riociguat, and inhaled iloprost plus sildenafil appear to be interesting and require further clinical confirmation. Other initial combinations of PAH-specific agents require large-scale clinical trials as well.

19 April 2016 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
Anton A. ShmaltsAnton A. Shmalts
Anton A. Shmalts
SGS. V. Gorbachevskiy
S. V. Gorbachevskiy
Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия